MIRA INFORM REPORT

 

 

Report Date :

18.08.2014

 

IDENTIFICATION DETAILS

 

Name :

ESAOTE CHINA LTD.

 

 

Formerly Known As :

MULTI GAIN TRADING LTD

 

 

Registered Office :

18/F., 135 Bonham Strand Trade Centre, 135 Bonham Strand, Sheung Wan

 

 

Country :

Hong Kong

 

 

Date of Incorporation :

16.12.1996

 

 

Com. Reg. No.:

20490912

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Trader of Medical Products

 

 

No of Employees :

20

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – June 1, 2014

 

Country Name

Previous Rating

(31.03.2014)

Current Rating

(01.06.2014)

Hong Kong

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

HONG KONG - ECONOMIC OVERVIEW

 

Hong Kong has a free market economy, highly dependent on international trade and finance - the value of goods and services trade, including the sizable share of re-exports, is about four times GDP. Hong Kong has no tariffs on imported goods, and it levies excise duties on only four commodities, whether imported or produced locally: hard alcohol, tobacco, hydrocarbon oil, and methyl alcohol. There are no quotas or dumping laws. Hong Kong's open economy left it exposed to the global economic slowdown that began in 2008. Although increasing integration with China, through trade, tourism, and financial links, helped it to make an initial recovery more quickly than many observers anticipated, its continued reliance on foreign trade and investment leaves it vulnerable to renewed global financial market volatility or a slowdown in the global economy. The Hong Kong government is promoting the Special Administrative Region (SAR) as the site for Chinese renminbi (RMB) internationalization. Hong Kong residents are allowed to establish RMB-denominated savings accounts; RMB-denominated corporate and Chinese government bonds have been issued in Hong Kong; and RMB trade settlement is allowed. The territory far exceeded the RMB conversion quota set by Beijing for trade settlements in 2010 due to the growth of earnings from exports to the mainland. RMB deposits grew to roughly 12% of total system deposits in Hong Kong by the end of 2013. The government is pursuing efforts to introduce additional use of RMB in Hong Kong financial markets and is seeking to expand the RMB quota. The mainland has long been Hong Kong's largest trading partner, accounting for about half of Hong Kong's total trade by value. Hong Kong's natural resources are limited, and food and raw materials must be imported. As a result of China's easing of travel restrictions, the number of mainland tourists to the territory has surged from 4.5 million in 2001 to 34.9 million in 2012, outnumbering visitors from all other countries combined. Hong Kong has also established itself as the premier stock market for Chinese firms seeking to list abroad. In 2012 mainland Chinese companies constituted about 46.6% of the firms listed on the Hong Kong Stock Exchange and accounted for about 57.4% of the Exchange's market capitalization. During the past decade, as Hong Kong's manufacturing industry moved to the mainland, its service industry has grown rapidly. Credit expansion and tight housing supply conditions have caused Hong Kong property prices to rise rapidly; consumer prices increased by more than 4% in 2013. Lower and middle income segments of the population are increasingly unable to afford adequate housing. Hong Kong continues to link its currency closely to the US dollar, maintaining an arrangement established in 1983. In 2013, Hong Kong and China signed new agreements under the Closer Economic Partnership Agreement, adopted in 2003 to forge closer ties between Hong Kong and the mainland. The new measures, effective from January 2014, cover services and trade facilitation, and will improve access to the mainland's service sector for Hong Kong-based companies.

 

Source : CIA

 

 


COMPANY NAME & ADDRESS

 

ESAOTE CHINA LTD.

 

ADDRESS:       18/F., 135 Bonham Strand Trade Centre, 135 Bonham Strand, Sheung Wan, Hong Kong.

 

PHONE:            852-2545 8386

 

FAX:                 852-2543 3068

 

E-MAIL:                        esaote@esaotechina.com

 

 

MANAGEMENT

 

Managing Director:  Mr. Michael Kurt Conroy

 

 

SUMMARY

 

Incorporated on:             16th December, 1996.

 

Organization:                 Private Limited Company.

 

Capital: Nominal:           HK$8,000,000.00

Issued:                          HK$8,000,000.00

 

Business Category:        Medical Product Trader.

 

Group Turnover:             EUR 300 - 350 million.

 

Employees:                   20.

 

Main Dealing Banker:     BNP Paribas, Hong Kong Branch.

 

Banking Relation:           Good.


ADDRESS

 

Registered Head Office:-

18/F., 135 Bonham Strand Trade Centre, 135 Bonham Strand, Sheung Wan, Hong Kong.

 

 

Holding Company

 

Esaote Spa, Italy.

 

 

Associated Companies

 

Esaote Asia Pacific Diagnostic Pvt. Ltd., India.

Esaote Benelux B.V., Netherlands.

Esaote Benelux N.V., Belgium.

Esaote Biomedical Deutschland GmbH, Germany.

Esaote Espana S.A.U., Spain.

Esaote Europe B.V., Netherlands.

Esaote France S.A.R.L., France.

Esaote Latinoamerica S.A., Argentina.

Esaote Medical Imaging B.V., Netherlands.

Esaote Medical S.A.S., France.

Esaote North America Inc., USA.

Shenzhen Esaote Medical Technology Co. Ltd., China.

 

 

BUSINESS REGISTRATION NUMBER

 

20490912

 

 

COMPANY FILE NUMBE

 

0581680

 

 

MANAGEMENT

 

Managing Director:  Mr. Michael Kurt Conroy

 

 

CAPITAL

 

Nominal Share Capital: HK$8,000,000.00 (Divided into 800,000 shares of HK$10.00 each)

 

Issued Share Capital: HK$8,000,000.00

 

 

SHAREHOLDERS

(As per registry dated 16-12-2013)

 

Name

 

No. of shares

Turquandia Ltd., Hong Kong.

 

1

Esaote S.p.A.

Via Angelo Siffredi, 58-16153 Genoa, Italy.

 

799,999

 

 

–––––––

 

Total:

800,000

======

 

 

DIRECTORS

(As per registry dated 16-12-2013)          

 

Name

(Nationality)

 

Address

Alberto BONI

11/F., Parkland Drive, Discovery Bay, Lantau Island, Hong Kong.

 

JIN Xuekun

1507, 5 Lou, 11 Jiaomen Beilu, Fengtai District, Beijing, 100068, China.

 

Michael Kurt CONROY

Flat A, 2/F., Coastline Villa, Peninsula Village, 30 Discovery Bay Road, Discovery Bay City, Lantau Island, Hong Kong.

 

Daniel NOVACEK

Jahnstr, 47 82319 Starnberg, Germany.

 

Renzo MUZI

Via Gardanesi, 106-22, Lipomo (Como) Italy.

 

 

SECRETARY

(As per registry dated 16-12-2013)

 

Name

Address

Co. No.

Tricor Tengis Ltd.

Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong.

0041027

 

HISTORY

 

The subject was incorporated on 16th December, 1996 as a private limited liability company under the Hong Kong Companies Ordinance.

Originally the subject was registered under the name of Multi Gain Trading Ltd., name was changed to the present style on 17th January, 1997.

Apart from these, neither material change nor amendment has been ever traced and noted.

 

 

OPERATIONS

 

Activities:                      Medical Product Trader.

 

Lines:                           All kinds of medical diagnostic equipment, etc.

 

Brand Name:                 Esaote.

 

Employees:                   20.

1,300. (Group)

 

Commodities Imported:  Europe, etc.

 

Markets:                       Hong Kong, China, other Asian countries, etc.

 

Annual Turnover:            EUR 300 - 350 million.

 

Terms/Sales:                 As per contracted.

 

Terms/Buying:               As per contracted.

 

MEMBERSHIPS:           The Hong Kong General Chamber of Commerce, Hong Kong.
[Membership No. HKE0372]

Italian Trade Commission, Italy.

The Italian Chamber of Commerce in Hong Kong and Macao, Hong Kong.

 

 

FINANCIAL INFORMATION

 

Nominal Share Capital: HK$8,000,000.00 (Divided into 800,000 shares of HK$10.00 each)

 

Issued Share Capital:     HK$8,000,000.00

 

Indebtedness:                US$4,000,000.00  (Total amount outstanding on all mortgages and charges as per last Annual Return dated 16-12-2013)

 

Mortgage or Charge:-

Date of Deed of Charge on Deposit: 06-09-2013

Amount:                        To secure the payment and discharge of all present and future indebtedness, obligations and/or liabilities of the Company

Property:                       The Company charges and agrees to charge to the Bank by way of first fixed charge and as continuing security for discharge of all Liabilities, all existing and future rights and interest of the Company in all the moneys from to time standing to the credit of the account no. 00001-207129-049-86 & 00001-207129-101-27

Mortgagee:                    BNP Paribas, Hong Kong Branch.

 

Profit or Loss:                Making a small profit every year.

 

Condition:                      Keeping in a satisfactory manner.

 

Facilities:                      Making rather active use of general banking facilities.

 

Payment:                      Met trade commitments as required.

 

Commercial Morality:     Satisfactory.

 

Banker:                         BNP Paribas, Hong Kong Branch.

 

Standing:                      Good.

 

 

GENERAL

 

Having issued 800,000 ordinary shares of HK$10.00 each, Esaote China Ltd. is wholly owned by Esaote S.p.A. [Esaote/Group, when including associates] which is an Italy-based company.

The subject is a member of the Esaote Group of companies.  It is engaged in the same lines of business as Esaote.

Esaote is one of the world’s leading producers of medical diagnostic systems.  It is well established as a Europe-based leading ultrasound manufacturer, and internationally acknowledged to be the world leader in dedicated MRI.  The Esaote Group is also one of the main players in the sector of Information Technology for healthcare.

In January 2006 a new Company - called Imaging S.p.A. - was created in order to purchase 100% of Esaote S.p.A. and its subsidiaries.  Imaging was created by financial investors (Intesa San Paolo S.p.A., IMI Investimenti S.p.A, Tower 7 S.a.r.l., Mps Venture SGR S.p.A, Banca Carige S.p.A) and by the managers of the Esaote Group.  During 2006 and 2007 Imaging S.p.A. was a shareholder of Esaote and had no operative functions.

In November 2009 Esaote is acquired by Tutti S.p.A., a consortium of investors led by Ares Life Sciences holding 40% of the share capital, and including IMI Investimenti S.p.A, Tower 7 S.a.r.l, MPS Venture SGR S.p.A, Banca Carige S.p.A and a group of Esaote management, holding a combined 60% stake.

During its life Esaote has undergone a steady growth, achieving net sales of about EUR 325,3 million in 2012 with a strong contribution of international sales equal to about 60%.  Almost 85% of Esaote’s consolidated sales are derived from highly competitive markets such as European countries, the United States and China.

Today the Esaote Group has about 1,300 employees, 50% of which work abroad.  The R&D structures employ about 270 qualified technicians (equal to 20% of total staff) and enjoy the co-operation of international research centres and universities.

The Group is engaged in the following business scope:-

·         Manufacturing & Process Engineering;

·         Medical device;

·         Software & ICT platforms;

·         Research & Development;

·         Satellite Activities; &

·         Marketing.

 

The business of the Group is active.  History in Hong Kong is about 17 years and eight months.

On the whole, in view of the parentage and background of the subject, consider it good for normal business engagements.

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.61.06

UK Pound

1

Rs.101.84

Euro

1

Rs.81.55

 

 

INFORMATION DETAILS

 

Analysis Done by :

SUM

 

 

Report Prepared by :

SHG

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.